For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Research and development | 15,330 | 18,210 | 18,400 | |
| General and administrative | 3,689 | 4,312 | 4,479 | |
| Total operating expenses | 19,019 | 22,522 | 22,879 | |
| Loss from operations | -19,019 | -22,522 | -22,879 | |
| Interest income, net | 980 | 1,480 | 1,690 | |
| Other income (expense), net | 1 | -23 | -16 | |
| Total other income | 981 | 1,457 | 1,674 | |
| Loss before (benefit) provision for income taxes | -18,038 | -21,065 | -21,205 | |
| Provision (benefit) for income taxes | - | -6 | 5 | |
| Net loss | -18,038 | -21,059 | -21,210 | |
| Unrealized loss on available for sale investments, net of tax | -101 | 69 | -61 | |
| Foreign currency translation gain | 2 | 1 | -2 | |
| Total other comprehensive loss | -99 | 70 | - | |
| Total comprehensive loss | -18,137 | -20,989 | -21,273 | |
| Basic EPS | -0.34 | -0.4 | -0.41 | |
| Diluted EPS | -0.34 | -0.4 | -0.41 | |
| Basic Average Shares | 53,331,766 | 52,993,238 | 52,010,827 | |
| Diluted Average Shares | 53,331,766 | 52,993,238 | 52,010,827 | |
PMV Pharmaceuticals, Inc. (PMVP)
PMV Pharmaceuticals, Inc. (PMVP)